Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Original Article from The New England Journal of Medicine — Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Related Articles
Fabry’s Disease | NEJM
A 44-year-old man presented with a 5-year history of heat intolerance and burning pain in his hands and feet. He had periumbilical angiokeratomas and nonnephrotic…
Ethical Challenges Associated with Pragmatic and Cluster RCTs | NEJM
Pragmatic and cluster RCTs offer opportunities for advancing research but present ethical challenges. Addressing these challenges requires multidisciplinary expertise and meaningful collaboration.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma | NEJM
The addition of zolbetuximab, an anti–claudin 18.2 antibody, to chemotherapy in gastric and gastroesophageal junction adenocarcinoma led to longer progression-free and overall survival than chemoth…
Primary Central Nervous System Vasculitis | NEJM
CNS vasculitis exists in medium- and large-vessel, small-vessel, and amyloid-deposition forms. Diagnosis is difficult, but the typical symptoms include acute focal deficits, cognitive impairment, a…
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia | NEJM
Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron-defic…
Targeting CSF1R in Chronic GVHD — Lessons in Translation | NEJM
Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured…
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease | NEJM
Colony-stimulating factor 1 receptor (CSF1R)–dependent monocytes and macrophages are key mediators of chronic graft-versus-host disease (GVHD), a major long-term complication of allogeneic hematopo…
Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths | NEJM
Evidence-based practices for reducing opioid-related overdose deaths include overdose education and naloxone distribution, the use of medications for the treatment of opioid use disorder, and…
Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia | NEJM
Long-term oxygen supplementation for at least 15 hours per day prolongs survival among patients with severe hypoxemia. On the basis of a nonrandomized comparison, long-term…
Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy | NEJM
In a pilot program in which 109,259 newborns were screened for metachromatic leukodystrophy, blood-spot samples were obtained for analysis and three newborns with MLD were…